Trials / Unknown
UnknownNCT03029533
Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer
An Open Label, Randomized, Single Dose, Parallel-group, Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following Subcutaneous Administration of DWJ108J in Patients With Prostate Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- Male
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety of DWJ108J (leuprolide acetate) and Leuplin DPS Inj administered subcutaneously in patients with prostate cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Leuprolide Acetate | DWJ108J, SC injection, once(Day1) |
| DRUG | Leuprolide Acetate | Leuplin DPS Inj, SC injection, once(Day1) |
Timeline
- Start date
- 2017-02-01
- Primary completion
- 2017-11-01
- First posted
- 2017-01-24
- Last updated
- 2017-01-24
Source: ClinicalTrials.gov record NCT03029533. Inclusion in this directory is not an endorsement.